Compare BUI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUI | AURA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.7M | 713.4M |
| IPO Year | 2011 | 2021 |
| Metric | BUI | AURA |
|---|---|---|
| Price | $28.25 | $7.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 71.5K | ★ 505.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.85 | $4.73 |
| 52 Week High | $30.80 | $9.54 |
| Indicator | BUI | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 56.00 |
| Support Level | $27.15 | $7.13 |
| Resistance Level | $29.00 | $7.81 |
| Average True Range (ATR) | 0.42 | 0.40 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 57.14 | 88.80 |
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure, and Power Opportunities business segments anywhere in the world and by employing writing (selling) call and put options.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.